CVM

Company Overview — What Does CEL SCI CORP Do?

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. CEL SCI CORP (CVM) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Geert R. Kersten and employs approximately 43 people, headquartered in Denver, Virginia. With a market capitalization of $29M, CVM is one of the notable companies in the Healthcare sector.

CEL SCI CORP (CVM) Stock Rating — Reduce (April 2026)

As of April 2026, CEL SCI CORP receives a Reduce rating with a composite score of 32.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CVM ranks #3,812 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CEL SCI CORP ranks #641 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CVM Stock Price and 52-Week Range

CEL SCI CORP (CVM) currently trades at $4.07. The stock lost $0.21 (4.9%) in the most recent trading session. The 52-week high for CVM is $13.48, which means the stock is currently trading -69.8% from its annual peak. The 52-week low is $0.18, putting the stock 2161.1% above its annual trough. Recent trading volume was 22K shares, suggesting relatively thin trading activity.

Is CVM Overvalued or Undervalued? — Valuation Analysis

CEL SCI CORP (CVM) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.21x, versus the sector average of 2.75x.

At current multiples, CEL SCI CORP trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CEL SCI CORP Profitability — ROE, Margins, and Quality Score

CEL SCI CORP (CVM) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -122.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -59.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CVM Debt, Balance Sheet, and Financial Health

CEL SCI CORP has a debt-to-equity ratio of 106.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.39x, suggesting adequate working capital coverage. Total debt on the balance sheet is $7M. Cash and equivalents stand at $11M.

CVM has a beta of -1.82, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for CEL SCI CORP is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CEL SCI CORP Revenue and Earnings History — Quarterly Trend

In TTM 2026, CEL SCI CORP reported revenue of $-628,830 and earnings per share (EPS) of $-0.68. Net income for the quarter was $-14M. Operating income came in at $-24M.

In Q1 2026, CEL SCI CORP reported revenue of $-87,789. Net income for the quarter was $5M. Operating income came in at $-5M.

In FY 2025, CEL SCI CORP reported revenue of $-648,944. Net income for the quarter was $25M. Operating income came in at $-25M.

In Q3 2025, CEL SCI CORP reported revenue of $-172,050. Net income for the quarter was $-6M. Revenue grew 9.8% year-over-year compared to Q3 2024. Operating income came in at $-5M.

Over the past 8 quarters, CEL SCI CORP has experienced revenue contraction from $0 to $-628,830. Investors analyzing CVM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CVM Dividend Yield and Income Analysis

CEL SCI CORP (CVM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CVM Momentum and Technical Analysis Profile

CEL SCI CORP (CVM) has a momentum factor score of 49/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

CVM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CEL SCI CORP (CVM) ranks #641 out of 838 stocks based on the Blank Capital composite score. This places CVM in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CVM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CVM vs S&P 500 (SPY) comparison to assess how CEL SCI CORP stacks up against the broader market across all factor dimensions.

CVM Next Earnings Date

No upcoming earnings date has been announced for CEL SCI CORP (CVM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CVM? — Investment Thesis Summary

The quantitative profile for CEL SCI CORP suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. High volatility (stability score 35/100) increases portfolio risk.

In summary, CEL SCI CORP (CVM) earns a Reduce rating with a composite score of 32.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CVM stock.

Related Resources for CVM Investors

Explore more research and tools: CVM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CVM head-to-head with peers: CVM vs AZN, CVM vs SLGL, CVM vs VMD.